<DOC>
	<DOC>NCT00557791</DOC>
	<brief_summary>The purpose of this study is to compare the safety and effectiveness of three doses of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with three doses of Lucentis速.</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Evaluating the Combination of Bevasiranib &amp; Lucentis Therapy in Wet AMD (CARBON)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients must be age 50 years or older Patients must have predominantly classic, minimally classic or occult with no classic lesions secondary to Age Related Macular Degeneration. The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen equivalent). Patients must be willing and able to return for scheduled monthly followup visits for twoyears. Prior pharmacologic treatment for AMD in the study (patients can not have previously received Avastin速/Lucentis速, Macugen速, or any other antiVEGF agents, steroid treatments, PDT, radiation treatment, or any experimental therapies for AMD in the study eye) Any intraocular surgery of the study eye within 12 weeks of screening Previous posterior vitrectomy of the study eye Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite treatment.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AMD</keyword>
	<keyword>ARMD</keyword>
	<keyword>Exudative Macular Degeneration</keyword>
	<keyword>Bevasiranib</keyword>
	<keyword>siRNA</keyword>
</DOC>